news
Successful kidney transplants from hepatitis C infected individuals
Transplantation followed by antiviral therapy cured hepatitis C in 100 percent of patients receiving kidneys from infected donors...
List view / Grid view
Hepatitis C (HCV)
Filter the results
news
Sofosbuvir found to be effective against Zika virus
A drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus...
news
FDA approves AbbVie’s Mavyret for hepatitis C
The FDA has approved Mavyret to treat adults with chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis...
news
BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
news
Costs for generic hepatitis C drugs in India paid back in 5 years
7 June 2017 | By Niamh Marriott, Junior Editor
Treatment with generic directly-acting antiviral drugs available in India increases lifespan while reducing lifetime health care costs
news
Gilead’s Phase II study showed 99% HCV cure rates
26 April 2017 | By Niamh Marriott, Junior Editor
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
news
AbbVie’s HCV/ compensated cirrhosis drug achieved 99% SVR12 rate
24 April 2017 | By Niamh Marriott, Junior Editor
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype and compensated cirrhosis (Child-Pugh A)...
news
AbbVie receives CHMP positive opinion for Hep C tablet combination
2 March 2017 | By Niamh Marriott, Digital Editor
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV)…
article
H is for Hepatitis C
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
H is for Hepatitis C - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in Hep C research...
news
AbbVie’s Hep C drug achieves high SVR rates after just 8 weeks of treatment
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load...
news
FDA approves Roche’s blood screening assay for donor screening
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
news
AbbVie’s HCV regimen receives FDA breakthrough designation
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
For the investigational, pan-genotypic regimen of glecaprevir /pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C...
news
AbbVie’s 8 week clinical trial speedy and successful for 98% of Hep C patients
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatment (SVR12)...
news
MSD’s Hepatitis C drug given green light for EU market
9 August 2016 | By MSD
Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with…
article
Hepatitis C: commitment to a cure
28 July 2016 | By Niamh Louise Marriott, Digital Content Producer
To find out more about Hepititis C, European Pharmaceutical Review spoke with Raquel Peck, CEO of the World Hepatitis Alliance and discovered exactly what it is being done to combat this widespread global health issue...